Key takeaways
- A new JAMA Psychiatry study reveals nearly one-third of eating disorder patients have used GLP-1 drugs.
- Over 10% of those surveyed admit to actively misusing the medications to severely restrict food intake.
- The findings highlight a critical screening gap on direct-to-consumer telehealth platforms.
- Telehealth providers are facing mounting pressure to implement stricter psychiatric and behavioral evaluations.
What happened
A landmark study published in JAMA Psychiatry has revealed that nearly one-third of individuals with eating disorders have used GLP-1 receptor agonists, such as Ozempic and Wegovy. Furthermore, researchers found that more than 10% of these individuals are actively misusing the medications to restrict their food intake. The findings have exposed a critical safety gap in online GLP-1 prescribing, placing immediate pressure on direct-to-consumer telehealth platforms to implement stricter psychiatric screening protocols.
Why it matters
This study highlights an urgent public health concern regarding how easily patients can obtain highly potent weight-loss medications online. Because GLP-1 drugs work by delaying gastric emptying and chemically suppressing appetite, they can be highly dangerous for individuals struggling with restrictive eating behaviors, anorexia, or bulimia.
For US consumers looking to buy GLP-1s online, this development is likely to change the digital onboarding experience. Many telehealth platforms currently rely on brief, self-reported online intake forms. In light of this data, platforms are facing intense scrutiny to move beyond basic automated questionnaires and implement robust psychological screenings to protect vulnerable patients from severe physical and psychological complications.
What the data says
The JAMA Psychiatry data outlines a troubling overlap between eating disorders and GLP-1 accessibility:
- High Prevalence: Nearly 33% (one-third) of individuals diagnosed with eating disorders reported having used a GLP-1 receptor agonist.
- Active Misuse: More than 10% of those surveyed admitted to misusing these medications specifically to facilitate severe food restriction.
- Screening Gaps: The study underscores that current virtual prescribing methods often fail to catch underlying psychiatric contraindications, relying heavily on self-reported height and weight without verifying behavioral health histories.
How it compares
Compared to traditional, in-person clinical settings where a physician might notice physical signs of malnutrition or have a long-term relationship with the patient, online telehealth platforms operate at a distinct disadvantage. To screen for risks, top-tier virtual providers will need to elevate their standards.
When you evaluate different options on our list of the cheapest telehealth GLP-1 platforms, you will find varying levels of clinical oversight. Some providers require video consultations with licensed medical professionals who can ask targeted questions about mental health, while others still rely entirely on text-based chat or quick asynchronous questionnaires.
Additionally, comparing compounded vs. brand-name semaglutide reveals another layer of risk: because compounded GLP-1s bypass traditional commercial insurance coverage, patients often pay out-of-pocket, meaning insurance companies do not perform their own diagnostic checks or prior authorization reviews that might otherwise flag a history of eating disorders.
How this fits the bigger picture
This safety revelation comes at a time of explosive growth for the virtual weight-loss industry. As documented in our coverage of how 1 in 5 US adults have tried a GLP-1, the normalization of these medications has made them household names. However, rapid commercialization has repeatedly drawn the eye of regulatory bodies.
The JAMA Psychiatry study aligns with broader systemic concerns about online medical oversight. We previously reported on safety signals in the global market, such as when Australia reported 62 deaths linked to GLP-1 drugs, emphasizing that while correlation does not equal causation, rigorous clinical monitoring is non-negotiable. Furthermore, as the FDA continues to monitor digital health marketing practices, telehealth platforms must adapt their clinical protocols or risk facing severe regulatory pushback.
What happens next
In the coming months, medical boards and digital health advocacy groups are expected to demand standardized psychiatric screening tools for all asynchronous weight-loss platforms. US consumers should prepare for more rigorous intake processes when signing up for GLP-1 therapy online. This may include mandatory screening questions regarding eating history, body image, and mental health, as well as required live video consultations before a prescription can be written or refilled.
CompareRx does not provide medical advice. If you or someone you know is struggling with an eating disorder or disordered eating, please contact a healthcare professional or reach out to a national support helpline for specialized care.